Angiotensin as a Vasopressor in Vasodilatory Shock

Slides:

Advertisements

Similar presentations

A Randomized Trial of Protocol-Based Care for Early Septic Shock Andrea Caballero, MD January 15, 2015 LSU Journal Club The ProCESS Investigators. N Engl.

Advertisements

Sepsis and Early Goal Directed Therapy

Severe Sepsis and Septic Shock Abdullah Alsakka EM.Consultant.

Stuart L. Goldstein, MD Professor of Pediatrics

Copyright 2008 Society of Critical Care Medicine

Diagnosis and Management of Shock Dr. Anas Khan Consultant, EM MBBS, MHA, ArBEM.

Corticosteroid Therapy in Acute illness Uptodate ICU-Acquired Weakness and Recovery from Critical Illness, N Engl J Med 2014 Hydrocortisone.

Poster Design & Printing by Genigraphics ® A Comparison of the Effects of Etomidate and Midazolam on the Duration of Vasopressor Use in.

Steroid Therapy.

Towards Global Eminence K Y U N G H E E U N I V E R S I T Y j 내과 R2 이지영.

Traitements non Antibiotiques du Choc Septique Djillali ANNANE, Hôpital Raymond Poincaré Garches,

Code Sepsis: Current Evidence Based Guidelines and the CMS Sepsis Core Measure Adult Patients - Abbreviated Updated May 26, 2017.

Yadegarynia, D. MD..

Code Sepsis: Current Evidence Based Guidelines and the CMS Sepsis Core Measure Adult Patients - Abbreviated Updated August 30, 2017.

Perspectives on Managing Polycythemia Vera for the Nurse Practitioner and Physician Assistant.

How the Latest Data in MDD Can Guide Treatment Decisions:

Steroids in Sepsis.

Monitoring and Modifying Treatment in PAH

51st Annual Scientific Session for the LIFE Investigators

Relative Adrenal Insufficiency

Clinical Considerations in the Management of EGFR-Mutated Advanced NSCLC.

PCP Perspectives Pathophysiologic Principles in the Management of Hyperkalemia.

An Update on Oral Prostanoids: Advancing Care for PAH?

Advances in Management of Perioperative Hypotension: It Takes a Team

Cardiogenic Shock.

The Clinical Enigma of Cardiogenic Shock

Glaucoma Progression.

Advances in Vasodilatory Shock:

Moderate-Intensity Statins for Dyslipidemia: How to Treat Today?

The Latest Data on Oral Prostacyclin Therapy in PAH

Metastatic Renal Cell Carcinoma

Managing Complex Hypertension: What Every Physician Should Know

Resistant Hypertension

New Treatments for CTEPH

All About PAH:.

Strategies to Improve Adherence and Persistence in the Treatment of Hypertension.

Adverse Neurohormonal Activation in HF Has Formed the Basis for Evidence-Based Pharmacologic Therapy

Selecting NOACs for High-Risk Patients

Panelists. One Size May Not Fit All: A New Aspirin Option for the High-Risk Patient.

A Focus on Polycythemia Vera for Nurse Practitioners and Physician Assistants.

Statins and New-Onset Diabetes REAL Updates and Clinical Implications

Updates in Pulmonary Arterial Hypertension

Treating Vasodilatory Shock in the ICU

Treatment Options to Consider

Managing Depression is a Team Effort:

Examining the Latest Evidence in PAH

Using Heart Rate as a Biomarker in Clinical Practice.

EARLY Combination Therapy in PAH: What Every Cardiologist Needs to Know.

Physiology Myocardial Oxygen Supply and Demanda,b.

Key Questions for nAMD Treatment Success

Novel Insulin/GLP-1 Combinations: Of Interest to the Primary Care Physician?

WHAT’S NEW WITH THE TREATMENTS FOR HIGH-RISK DYSLIPIDEMIA?

Getting to Grips With the Science of CGRP and Migraine

The Road to Quality Improvement in HER2-Positive Breast Cancer

T2DM, CV Risk, and SGLT2 Inhibition in the Spotlight

Oral Prostacyclin Pathway Agents in PAH

Iron Deficiency in Heart Failure

PeaceHealth Southwest Hospital/Carson Tahoe Medical Center

Diagnosis, Evaluation, and Therapy for Severe Refractory Eosinophilic Asthma.

Patient Stories in PAH: Sequential Therapy in a FC II Patient

Saving the Day.

Breaking Barriers in PAH: Role of Novel Early Treatment Strategies

Real-World Evidence.

Clinical Comparisons in CTEPH

Merging the Art and Science of Managing nOH in Clinical Practice

What's New in PAH?.

My PAH Patient.

PCSK9 Inhibitors and Real-World Evidence

Can the Dual vs Triple Therapy Controversy in Patients With AF Undergoing PCI Be Put to Rest?

Presentation transcript:

Angiotensin as a Vasopressor in Vasodilatory Shock

Background: Defining Shock

Types of Shock

Causes of Vasodilatory Shock

Pathophysiology of Vasodilatory Shock

Hemodynamic Profiles of Types of Shock

Homeostasis Systems Involved in Restoring Effective BP

Vasodilatory Shock Goals of Treatment

Vasodilatory Shock Treatment Strategies

Management of Vasodilatory Shock

Fluid Therapy as Initial Strategy

Recommendations for Vasoactive Medications

VASST Study

Predictors of Response to Vasopressin in Adults With Septic Shock

Outcomes Associated With the Use of Catecholamines for the Treatment of Hypotension in Patients With Shock

Vasopressor Dose Requirement

ADRENAL Trial

Study: Hydrocortisone and Fludrocortisone in Patients With Septic Shock

Selepressin

Effects of the V1a Agonist FE 202158 in Patients With Septic Shock (Phase 2a)

Selepressin Evaluation Program for SEPSIS-ACT

Angiotensin II

Restoration of Effective Blood Pressure

Mechanism of Action of Angiotensin II

Angiotensin II Trials

ATHOS-3 Primary Outcome

ATHOS-3 Additional Endpoints

Ang II Responders Survival by Ang I:Ang II Ratio at Baseline

Low ACE, High Ang I/Ang II

Angiotensin II: Current Status

Take-Home Messages

Abbreviations

Abbreviations (cont)